Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price target from $80 to $142.
Raymond James analyst Chris Raymond maintains Monopar Therapeutics (NASDAQ:MNPR) with a Strong Buy and raises the price target from $80 to $142.